Introduction: Antimullerian hormone (AMH) strongly correlates with ovarian reserve and response to controlled ovarian stimulation. Emerging data suggests that serum AMH level may also predict ART outcomes. However, AMH is characteristically elevated in PCOS women and it is unknown whether it may predict live birth outcomes in this population. Methods: This was a retrospective cohort study of 184 PCOS women (Rotterdam criteria) who underwent their first fresh IVF/ICSI cycle. Women were divided into 3 groups according to the <25th (low), 25 to 75th (average), or > 75th (high) percentile of serum AMH concentration. Cycle stimulation parameters and reproductive outcomes were compared between groups. Results: Women in the low serum AMH group were older than those in the average or high AMH (p < 0.05), and required greater gonadotropin dose for stimulation compared to the high AMH group (p < 0.05). Women with high AMH had greater testosterone level compared to women in the low or average AMH groups. No differences were noted between groups in terms of maximal E2, oocytes retrieved and fertilization rate. However, low serum AMH women had significantly greater live birth rates (p < 0.05) and showed a trend towards greater clinical pregnancy rates compared to women in the average and high AMH groups (p = 0.09). The significant association of AMH with live birth rate remained after adjusting for age, BMI, day of transfer and number of embryos transferred. Conclusions: In PCOS women, elevated AMH concentrations are associated with hyperandrogenism and lower live birth rates.

This case report presents the case of a 28-year-old man who developed scurvy during the coronavirus disease 2019 (COVID-19) pandemic. Scurvy is a disease resulting from a nutritional deficiency of vitamin C (ascorbic acid). It is a rare condition, whose signs and symptoms can vary from patient to patient. The treatment is vitamin C supplementation, which is often followed by a swift recovery. To our knowledge, this is the first reported case of scurvy during the COVID-19 pandemic. This article highlights a rare acquired bleeding disorder, which may manifest more commonly during a pandemic due to food scarcity or stay-athome mandates in those already at risk.

Mucor is a well-known opportunistic organism; however, it rarely infects the gastrointestinal (GI) tract. Although known to transiently colonize healthy immunocompetent individuals, the incidence of mucormycosis is increasing in patients with hematologic malignancies, which can have serious consequences in an immunocompromised host. This abstract presents 3 patients from a single institution with Mucor colonization of their stool.Each patient had a hematologic malignancy and was neutropenic when diagnosed with Mucor colonization of the stool. The duration of neutropenia ranged from 1 to 76 days with median of 31 days at the time of diagnosis. Patients were observed for symptoms of GI tract invasion, and they received antimold prophylaxis while neutropenic. Despite GI shedding, no mold sinusitis or pneumonia or gastroenteritis was noted. Gastrointestinal mucormycosis was never noted during their hospital course.This case series emphasizes the importance of not dismissing mold colonization of the stool in a patient with prolonged neutropenia who is at high risk of invasive GI tract mucormycosis. When stool cultures grow Mucor in patients with prolonged neutropenia, anti-Mucor therapy is indicated and may prevent invasive mold infection during the period of risk.